could important living kennedy disease huntington disease hd similar spinal bulbar muscular atrophy also cag triplet repeat disorder previously treatment successful drug target cause hd press release isis pharmaceuticals initiates clinical study isis htt rx patients huntington disease first therapy designed directly target cause disease isis earns million milestone payment roche carlsbad calif july prnewswire isis pharmaceuticals inc nasdaq isis today announced initiated phase clinical study isis httrx patients huntington disease hd isis httrx first therapy enter clinical development designed directly target cause disease reducing production protein responsible hd hd rare genetic neurological disease patients experience deterioration mental abilities physical control presently disease modifying treatments hd current therapies focused treating disease symptoms isis httrx granted orphan drug designation european medicines agency treatment patients hd orphan drug designation granted products designed diagnose prevent treat life threatening serious conditions affect five persons european union although toxic protein produced huntingtin htt gene hd patients target interest many years therapies advanced clinical trials treat underlying cause disease antisense technology enabled discover develop isis httrx first therapeutic approach designed treat genetic cause hd together roche committed investigating approach treat patients hd devastating disease typically affects generations families said frank bennett ph senior vice president research isis pharmaceuticals initiating clinical study isis httrx patients hd first step developing treatment could significantly impact patient disease also important milestone collaboration roche advance program continue benefit roche scientific expertise developing therapeutics neurodegenerative conditions said lynne parshall chief operating officer isis pharmaceuticals randomized placebo controlled dose escalation phase clinical study evaluate safety activity isis httrx patients early stage hd study isis httrx administered intrathecally injection directly cerebral spinal fluid intrathecal administration antisense drugs shown well tolerated multiple clinical studies patients initial development antisense drug huntington disease came longstanding productive partnership isis chdi advancement clinical trial testament isis perseverance scientific expertise said robi blumenstein president chdi management oversees activities chdi foundation nonprofit research organization exclusively dedicated development therapies slow progression hd exciting therapeutic candidates grounded biology huntington disease finally making way clinical trial isis roche roche isis collaborating develop antisense drugs treat hd alliance combines isis antisense expertise roche scientific knowledge developing neurodegenerative therapeutics initiation phase study isis httrx isis earned million milestone payment roche date isis earned million upfront milestone payments relationship roche eligible earn additional milestone payments drug progresses development well royalties sales isis httrx commercialized roche option license isis httrx isis completion phase study prior option exercise isis responsible discovery development isis httrx roche exercises option assume responsibility global development regulatory commercialization activities drug chdi foundation inc provided financial scientific support isis hd drug discovery program development collaboration isis time chdi reimbursed support isis program milestone payments received isis isis httrx huntington disease isis httrx gen antisense drug development treatment huntington disease isis httrx designed reduce production forms huntingtin protein protein responsible hd isis httrx offers unique approach treat patients hd hd rare genetic progressive neurological disease resulting deterioration mental abilities physical control hd referred triplet repeat disorder one large family genetic diseases certain gene sequences mistakenly repeated hd gene encodes htt protein contains trinucleotide sequence repeated gene times resulting htt protein toxic gradually damages neurons brain symptoms hd usually appear ages years continually worsen year period ultimately weakened individual succumbs pneumonia heart failure complications presently effective disease modifying treatment current approaches focus managing severity disease symptoms